The effect of human IL-17F on growth of human hepatocarcinoma xenograft tumor in nude mice.
- Author:
Yu-Feng XIE
1
;
Wei-Hua SHENG
;
Jing-Cheng MIAO
;
Ji-Cheng YANG
Author Information
1. Department of Cellular and Molecular Biology, Medical School, Soochow University, Suzhou, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cell Line, Tumor;
Cell Proliferation;
Genetic Therapy;
Humans;
Interleukin-17;
genetics;
Liver Neoplasms, Experimental;
pathology;
therapy;
Mice;
Mice, Nude;
Retroviridae;
genetics;
Vascular Endothelial Growth Factor A;
analysis;
Xenograft Model Antitumor Assays
- From:
Chinese Journal of Biotechnology
2006;22(5):772-778
- CountryChina
- Language:Chinese
-
Abstract:
The human interleukin-17F(hIL-17F) gene was amplified by RT-PCR from PHA-activated human peripheral blood mononuclear cells (PBMCs). It was then subcloned into the retrovirus vector pSIV-1. The pSIV-1/hIL-17F together with its two-helper virus vectors pHIT456 and pHIT60 cotransfected into the package cell 293T by lipofectin to produce mature recombinant retrovirus, which was then used to infect SMMC-7721 hepatocarcinoma cells (HCCs), and the cells were selected in the presence of G418. The integration, transcription, expression of hIL-17F gene in SMMC-7721 cells was identified by PCR, RT-PCR and Western blot respectively. MTT and FCM showed that hIL-17F couldn't alter the proliferation and cell cycle of SMMC-7721 cells, but ELISA showed that it could down-regulate IL-6, IL-8 and VEGF expression. The effect of rhIL-17F supernatant on growth suppressing of ECV304 cells was observed by MTT. The experiment of human hepatocarcinoma xenograft tumor in nude mice showed that the formation and growth rates of hIL-17F-transgenic SMMC-7721 showed an obvious decline, and VEGF and CD34 expression and angiogenesis of the transgenic neoplasms was also evidently defined. hIL-17F can markedly inhibit the growth of human hepatocarcinoma xenograft tumor in nude mice by antiangiogenesis. This study provided an experimental evidence for further conducting tumor gene therapy by targeting vascularity and exploiting antiangiogenic novel medicine related to hIL-17F.
